Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. William H. Collier

Market Cap

634.09 Million USD

Sector

Healthcare

Website

https://www.arbutusbio.com

Last Update

2/22/2024, 12:00:00 PM

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.

Read More

Overview

Value

0

Growth

20

Health

42

Management

0

Analyst Opinion

46

Total

35

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • Altman-Z score suggests a risk of bankruptcy
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Dividend could be at risk

Market Peers

ABUS

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

N/A

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Sell

Share Buybacks

N/A

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

0

  • Estimated intrinsic-value of N/A is lower than current price ( 3.36 USD)
  • Free-cashflow-yeild of -18.33% is worse than the market average (4.7%)
  • Margin-of-safety of N/A is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 2.6 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-18.33%

PE/Earnings Growth

N/A

Price/Book

4.42x

Growth

Growth Score

20

  • Earnings growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

42

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Debt repayments significantly impact cashflow

Altman Z Score

0.00

Piostroski Score

1.00

Debt/Equity

0.02x

Current Assets/Liabilities

14.32x

Free Cashflow/Total Debt

0.00x

Debt/Capital

0.02x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

N/A

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

0

  • Return-on-capital-employed of -32.40% is lower than the market average (10%)
  • Return-on-equity of -87.92% is lower than the market average (15%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

68.95%

5 Year Price Volitility

15.49%

Return On Assets

-72.86%

Return On Capital Employed

-32.40%

Return On Equity

-87.92%

Return On Free Cashflow

N/A

Return On Investments

-182.30%

Social Sentiment

Social Sentiment Score

30

Twitter Sentiment

0.00

Stocktwits Sentiment

60.00

Analysts

Analyst Opinion

46

  • Ratings consensus is Sell

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Arbutus Biopharma Corporation

Currency

USD

Beta

2.115437

Vol Avg

585253

Ceo

Mr. William H. Collier

Cik

0001447028

Cusip

03879J100

Exchange

NASDAQ Global Select

Full Time Employees

96

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2007-07-26

Address

701 Veterans Circle

City

Warminster

State

PA

Country

US

Zip

18974

Phone

267 469 0914

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies